The move is part of the company’s strategy of taking its own products wherever there’s a suitable market for selling them, according to Ioan Nani, the company’s general manager.
In the past 25 years, Antibiotice has invested over EUR120 million to upgrade its production capacities and the entire execution process and for the next 8-10 years the company aims to invest over RON400 million.
The Romanian drug maker in 1H/2023 posted RON315.9 million turnover, the equivalent of a 27% increase against 1H/2022, while net profit went up by 82.8% to RON62 million.
The company’s official estimates Antibiotice will hit RON250 million turnover in 2030, double the current level, by boosting capacities and doubling production in Romania.
Antibiotice Iasi has a RON792 million capitalization, after the company’s shares have added 110.2% since the start of the year amid deals worth RON27 million.
(English version by Catalina Apostoiu)